Table 2.
Univariate and multivariate analysis of overall survival for the 1,392 patients.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Age (continuous) | 0.992 | 0.983–1.002 | 0.988 | 0.977–1.000 | ||
| Histology | ||||||
| SCC | 1 (reference) | 1 (reference) | ||||
| nSCC | 2.060 | 1.638–2.591 | < 0.001 | 2.381 | 1.814–3.127 | < 0.001 |
| pT classification | ||||||
| pT1a | NA | NA | NA | NA | NA | NA |
| pT1b | 1 (reference) | 1 (reference) | ||||
| pT2a | 2.085 | 1.421–3.061 | < 0.001 | 2.181 | 1.401–3.396 | < 0.001 |
| pT2b | 1.881 | 1.426–2.480 | < 0.001 | 2.332 | 1.621–3.356 | < 0.001 |
| pT2a | 1 (reference) | 1 (reference) | ||||
| pT2b | 0.902 | 0.645–1.261 | 0.546 | 1.069 | 0.712–1.606 | 0.746 |
| PLN metastasis | ||||||
| Negative | 1 (reference) | 1 (reference) | ||||
| Positive | 1.483 | 1.097–2.005 | 0.011 | 1.997 | 1.366–2.920 | < 0.001 |
| PALN metastasis | ||||||
| Negative/not performed | 1 (reference) | 1 (reference) | ||||
| Positive | 2.474 | 1.705–3.590 | < 0.001 | 1.668 | 1.017–2.737 | 0.043 |
| Tumor diameter | ||||||
| ≤ 40 mm | 1 (reference) | 1 (reference) | ||||
| > 40 mm | 1.629 | 1.293–2.052 | < 0.001 | 1.283 | 0.978–1.683 | 0.072 |
| LVSI | ||||||
| Negative | 1 (reference) | 1 (reference) | ||||
| Positive | 1.977 | 1.290–3.029 | 0.002 | 1.336 | 0.827–2.157 | 0.237 |
| Stromal invasion | ||||||
| ≤ 1/2 | 1 (reference) | 1 (reference) | ||||
| > 1/2 | 2.122 | 1.425–3.161 | < 0.001 | 1.367 | 0.856–2.183 | 0.190 |
| Ovarian metastasis | ||||||
| Negative/preserved | 1 (reference) | 1 (reference) | ||||
| Positive | 3.682 | 2.253–6.019 | < 0.001 | 2.254 | 1.232–4.122 | < 0.001 |
| Corpus invasion | ||||||
| Negative | 1 (reference) | 1 (reference) | ||||
| Positive | 1.709 | 1.337–2.185 | < 0.001 | 1.266 | 0.935–1.715 | 0.127 |
| Adjuvant therapy | ||||||
| CCRT | 1 (reference) | 1 (reference) | ||||
| CT | 1.071 | 0.804–1.427 | 0.637 | 0.837 | 0.596–1.176 | 0.306 |
| RT | 1.024 | 0.766–1.368 | 0.875 | 1.119 | 0.806–1.555 | 0.501 |
| None | 0.884 | 0.427–1.685 | 0.707 | 1.120 | 0.504–2.487 | 0.781 |
| CT | 1 (reference) | 1 (reference) | ||||
| RT | 0.955 | 0.694–1.315 | 0.779 | 1.337 | 0.917–1.948 | 0.131 |
| None | 0.825 | 0.427–1.594 | 0.566 | 1.337 | 0.591–3.025 | 0.485 |
| RT | 1 (reference) | 1 (reference) | ||||
| None | 0.863 | 0.446–1.671 | 0.863 | 1.000 | 0.443–2.260 | 0.999 |
| Peritoneal cytology | ||||||
| Negative | 1 (reference) | |||||
| Positive | 2.126 | 1.327–3.405 | 0.002 | |||
HR Hazard ratio, CI confidence interval, SCC squamous cell carcinoma, nSCC non-squamous cell carcinoma, PLN pelvic lymph node, PALN para-aortic lymph node, LVSI lymphovascular space invasion, CCRT concurrent chemoradiotherapy, CT chemotherapy, RT radiotherapy.